Trump Tariffs Deal Heavy Blow to Berkshire Hathaway’s Consumer Goods Business
BlockBeats News, August 2 — Berkshire Hathaway (BRK.A.N, BRK.B.N), led by Warren Buffett, stated that its consumer goods business has been impacted by U.S. President Trump’s trade policies, which have raised tariffs on imported goods. The conglomerate’s consumer products division—which includes brands such as Fruit of the Loom, Jazwares, and Brooks Sports—saw its second-quarter revenue drop 5.1% year-on-year to $189 million, mainly due to declining sales, the effects of tariffs, and business restructuring.
Berkshire noted that the tariff policies have caused delays in order deliveries. However, the company pointed out that athletic footwear brand Brooks achieved a remarkable 18.4% revenue increase this quarter, thanks to higher sales volumes. Given Berkshire’s diverse business portfolio spanning multiple sectors, its performance is often viewed as a barometer of the U.S. economy and closely watched by investors. At Berkshire’s annual meeting in May this year, Buffett strongly supported free trade, stating that tariffs should not be used as “weapons” and emphasizing that “balanced trade is good for the world.” (Jin10)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
